--- title: "Lanifibranor’s Emerging Role in the MASH Market: Physician Sentiment and Uptake Potential Support a Buy Rating Despite Cash Constraints" type: "News" locale: "en" url: "https://longbridge.com/en/news/280477150.md" description: "LifeSci Capital analyst Rami Katkhuda has maintained a Buy rating on Inventiva, setting a price target of $14.00. His positive outlook is based on lanifibranor's potential in the MASH market, supported by physician sentiment from a survey of 68 specialists. Despite competition, doctors expect to prescribe lanifibranor more frequently, especially if Phase III data confirms its efficacy. The drug's favorable safety profile and potential uptake in specific patient groups further enhance its commercial prospects, despite current cash constraints. Truist Financial also initiated coverage with a Buy rating and a $13.00 price target." datetime: "2026-03-25T12:56:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280477150.md) - [en](https://longbridge.com/en/news/280477150.md) - [zh-HK](https://longbridge.com/zh-HK/news/280477150.md) --- # Lanifibranor’s Emerging Role in the MASH Market: Physician Sentiment and Uptake Potential Support a Buy Rating Despite Cash Constraints LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Inventiva today and set a price target of $14.00. ### Claim 30% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Rami Katkhuda has given his Buy rating due to a combination of factors related to lanifibranor’s positioning in the emerging MASH market and physician sentiment. His survey of 68 U.S. specialists treating over 16,000 MASH patients indicates that, despite competition from Wegovy and Rezdiffra, overall use of novel therapies is rising and doctors anticipate prescribing lanifibranor more often, particularly driven by its anticipated impact on fibrosis. Moreover, physicians project meaningful uptake in F2/3 patients if Phase III NATiV3 data confirm or exceed the Phase IIb efficacy, with utilization potentially reaching roughly one-third of this population at higher fibrosis response rates. The safety profile, including relatively limited clinically significant weight gain, and the perceived role of lanifibranor in key subgroups such as F3, lean MASH, or patients intolerant to Rezdiffra or GLP-1s, supports a substantial commercial opportunity that underpins his constructive view on the stock despite the current cash runway constraints. Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Disc Medicine, and Viridian Therapeutics. According to TipRanks, Katkhuda has an average return of 32.0% and a 53.85% success rate on recommended stocks. In another report released on March 19, Truist Financial also initiated coverage with a Buy rating on the stock with a $13.00 price target. ### Related Stocks - [IVA.US](https://longbridge.com/en/quote/IVA.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) ## Related News & Research - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md) - [Assessing Inventiva (ENXTPA:IVA) Valuation After Recent Share Price Volatility](https://longbridge.com/en/news/286962960.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md) - [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)